Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

• NeuroKey-3™ measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and more.
• NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.
• NeuroKey-3™ is now commercially available through Inoviv for drug developers to gather valuable data for their clinical trials.

LONDON, March 1, 2024 /PRNewswire/ -- Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma. The launch of NeuroKey-3™ signifies an important milestone in Inoviv's mission to generate novel molecular insights that transform drug development and healthcare globally. Inoviv will unveil NeuroKey-3™ at AD/PD 2024 on March 5, 2024.

NeuroKey-3™ is the world's first commercially available disease-targeted assay providing absolute quantification from plasma of a unique set of proteins linked to Alzheimer's Disease and Dementia. The comprehensive assay and end-to-end service delivers highly robust and reproducible data to quantify low-level analytes and provides clinical researchers with a full biomarker report containing statistical analysis, graphical data representations, correlation matrices, and quantitative values.

"NeuroKey-3 significantly accelerates clinical trial timelines and offers neurological drug developers a game-changing biomarker strategy that can measure proteins which pharmaceutical companies care about, at the precision needed to enable decision-making and FDA submissions," said Inoviv CEO & co-founder Michael Dove. "NeuroKey-3 provides highly accurate and fully quantitative insights into proteins linked to neurodegeneration and can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites."

For more information about NeuroKey-3™, find us at:

• Biomarkers 2024: March 1, 2024, London, UK.
• AD/PD 2024: March 5, 2024, Lisbon, PORT.
• Email us at [email protected] or visit us at www.inoviv.com

About Inoviv

Our mission is to generate novel molecular insights that transform drug development and healthcare globally. We work with leading pharma and biotech companies to deliver robust and quantitative biomarker analysis to accelerate the development of life-changing treatments.

We are setting the standard for targeted proteomics. Whether you want to discover treatment-responsive biomarkers, create a custom panel, scale up and validate your own assay for clinical studies, or take advantage of our pre-validated panels, we're your trusted proteomics partners. https://www.inoviv.com/

SOURCE Inoviv